Pancreatic Cancer pp 1079-1092 | Cite as

Adjuvant Chemoradiation Therapy for Pancreatic Cancer

  • Naimish Pandya
  • Michael C. Garofalo
  • William F. Regine
Reference work entry


Despite newer treatment modalities, overall outcome for pancreatic cancer has changed very little during the past thirty years. Surgery remains the mainstay, but delivery of adjuvant postoperative therapy has been shown to be essential for any long-term survival. Large prospective randomized studies have revealed conflicting data on whether chemotherapy alone or combination chemoradiation is optimal. Unfortunately, marked discrepancies exist with patient selection as well as trial design among these studies, resulting in inadequate comparisons of their conclusions. Nevertheless, similar to other gastrointestinal malignancies, it appears that adjuvant combination chemoradiation is superior to chemotherapy alone when the data is critically analyzed. This critical examination of the published data to date is provided in the forthcoming chapter, along with an assessment of what is needed for future trials to determine the optimal adjuvant treatment modality and improve overall outcome for pancreatic cancer patients.


Pancreatic Cancer Radiation Therapy Oncology Group Positive Surgical Margin Pancreatic Cancer Patient Advanced Pancreatic Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008;58(2):71–96.CrossRefPubMedGoogle Scholar
  2. 2.
    Warshaw AL, Fernandex del-Castillo C: Pancreatic adenocarcinoma. N Engl J Med 1992;326(7):455–465.CrossRefPubMedGoogle Scholar
  3. 3.
    Foo ML, Gunderson LL, Nagorney DM et al.: Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5-flurouracil. Int J Radiat Oncol Biol Phys 1993;26:483–489.CrossRefPubMedGoogle Scholar
  4. 4.
    Griffin JF, Smalley SR, Jeweall W, et al.: Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990;66:56–61.CrossRefPubMedGoogle Scholar
  5. 5.
    Tepper J, Nardi G, Suit H: Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer 1973;37(3):1519–1524.CrossRefGoogle Scholar
  6. 6.
    Whittington R, Bryer MP, Haller DG, et al.: Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1991;21(5):1137–1143.CrossRefPubMedGoogle Scholar
  7. 7.
    Hishinuma S, Ogata Y, Tomikawa M, et al.: Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 2006;10(4):511–518.CrossRefPubMedGoogle Scholar
  8. 8.
    Mulcahy MF: Adjuvant therapy for pancreas cancer: Advances and Controversies. Seminars Oncol 2007;34:321–326.CrossRefGoogle Scholar
  9. 9.
    Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–730.CrossRefPubMedGoogle Scholar
  10. 10.
    Krook JE, Moertel CG, Gunderson LL, et al.: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709–715.CrossRefPubMedGoogle Scholar
  11. 11.
    Moertel CG, Childs DS Jr, Reitemeier RJ, et al.: Combined 5-flurouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;2:865–867.CrossRefPubMedGoogle Scholar
  12. 12.
    Hasalam JB, Cavenaugh PJ, Stroup SL: Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas. Cancer 1973;32:1341–1345.CrossRefGoogle Scholar
  13. 13.
    Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987;59:2006–2010.Google Scholar
  14. 14.
    Klinkenbijl JH, Jeekel J, Sahmoud T, et al.: Adjuvant radiotherapy and 5-flurouracil after curative resection of cancer of the pancreas and periampullary region. Ann Surg 1999;230(6):776–782.CrossRefPubMedGoogle Scholar
  15. 15.
    Regine WF, Winter KA, Abrams RA, et al.: Flurouracil vs gemcitabine chemotherapy before and after flurouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial [published correction appears in JAMA. 2008; 299(18):JCX80010]. JAMA 2008;299(9):1019–1026.CrossRefPubMedGoogle Scholar
  16. 16.
    Neoptolemos JP, Dunn JA, Stocken DD, et al.: Adjuvant chemoradiotherapy and chemotherapy in respectable pancreatic cancer: a randomized trial. Lancet 2001;358:1576–1585.CrossRefPubMedGoogle Scholar
  17. 17.
    Oettle H, Post S, Neuhaus P, et al.: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA 2007;297:267–277.CrossRefPubMedGoogle Scholar
  18. 18.
    Douglass HO, Strablein DM: Ten year follow-up of first generation surgical adjuvant studies of the Gastrointestinal Tumor Study Group. In: Adjuvant Therapy of Cancer. Vol 4. Salmon SE, ed. Philadelphia, PA: WB Saunders, pp. 404–415, 1990.Google Scholar
  19. 19.
    Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987;59:2006–2010.Google Scholar
  20. 20.
    Garofalo MC, Regine WR, Tan MT: On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. Ann Surg 2006;244(2):332–333.CrossRefPubMedGoogle Scholar
  21. 21.
    Sperti C, Pasquali C, Piccoli A, et al.: Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997;21(2):195–200.CrossRefPubMedGoogle Scholar
  22. 22.
    Spalding DR.: Pancreatic and periampullary cancers: treatment and outcome. Br J Hosp Med (Lond) 2006;67(1):14–20.Google Scholar
  23. 23.
    Neoptolemos JP, Stocken DD, Friess F, et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 2004;350(12):1200–1210.CrossRefPubMedGoogle Scholar
  24. 24.
    Oettle H and Neuhaus P: Adjuvant therapy in pancreatic cancer: a critical appraisal. Drugs 2007;67(16):2293–2310.CrossRefPubMedGoogle Scholar
  25. 25.
    Abrams RA, Winter KA, Regine WF, et al.: Radiotherapy quality assurance review and survival. Proceedings of ASTRO. Int J Radiat Oncol Biol Phys 2006;66(3):S22.Google Scholar
  26. 26.
    Neuhaus P, Riess H, Post S, et al.: CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol 2008;26 Suppl, Abstract No. LBA4504.Google Scholar
  27. 27.
    Berger AC, Winter KA, Hoffman J, et al.: Post-resection CA 19–9 predicts overall survival (OS) in patients treated with adjuvant chemoradiation: A secondary endpoint of RTOG 9704. J Clin Oncol 2007;25(18S): Abstract 4522.Google Scholar
  28. 28.
    Regine WF, Garcia M, Berger AC, et al.: Post-resectional CA 19–9 values <90 are associated with significantly worse survival in patients with pancreatic carcinoma treated with adjuvant therapy on RTOG 9704 – implications for current and future trials. Int J Radiat Oncol Biol Phys 2007;69(3):S78 Abstract No. 137.CrossRefGoogle Scholar
  29. 29.
    Hsu CC, Herman JM, Corsini MM, et al.: Benefit of adjuvant chemoradiation therapy for pancreatic adenocarcinoma: The Johns-Hopkins Hospital-Mayo Clinic collaborative study of 1,045 patients. ASCO GI Symposium: Abstract No. 124, 2008.Google Scholar
  30. 30.
    Picozzi VJ, Abrams RA, Traverso LW, et al.: ACOSOG Z05031: Report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5-FU, and alpha-interferon. J Clin Oncol 2008;26 Suppl: Abstract No. 4505.Google Scholar
  31. 31.
    Mehta VK, Fisher GA, Ford JM, et al.: Adjuvant radiotherapy and concomitant 5-flurouracil by protracted venous infusion for resected pancreatic cancer. Int J Radiat Oncol Biol Phys 2000;48:1483–1487.CrossRefPubMedGoogle Scholar
  32. 32.
    Reni M, Passoni P, Bonetto E, et al.: Final results of a prospective trial of a PEGF (cisplatin, epirubicin, 5-flurouracil, gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma. Oncology 2005;68:239–245.CrossRefPubMedGoogle Scholar
  33. 33.
    Greco JA, Castaldo ET, Feurer ID, et al.: Survival benefit with adjuvant radiation therapy in surgically resected pancreatic cancer. ASCO GI Symposium: Abstract No. 109, 2007.Google Scholar
  34. 34.
    McGinn CJ, Zalupski MM, Shureigi J, et al.: Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001;19:4202–4208.PubMedGoogle Scholar
  35. 35.
    Blackstock AW, Mornex F, Partensky C, et al.: Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer 2006;95:260–265.CrossRefPubMedGoogle Scholar
  36. 36.
    Murphy JD, Adusumilli S, Griffith KA, et al.: Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007;68:801–808.CrossRefPubMedGoogle Scholar
  37. 37.
    Wolff RA, Varadhachary GR, Evans DB: Adjuvant therapy for adenocarcinoma of the pancreas: analysis of reported trials and recommendations for future progress. Ann Surg Oncol 2008;15:2773–2786.CrossRefPubMedGoogle Scholar
  38. 38.
    Sohn TA, Yeo CJ, Cameron JL, et al.: Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567–579.CrossRefPubMedGoogle Scholar
  39. 39.
    Neoptolemos JP, Stocken DD, Dunn JA, et al.: Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234:758–768.CrossRefPubMedGoogle Scholar
  40. 40.
    Kuhlmann KF, de Castro SM, Wesseling JG, et al.: Surgical treatment of pancreatic adenocarcinoma: actual survival and prognostic factors in 343 patients. Eur J Cancer 2004;40:549–558.CrossRefPubMedGoogle Scholar
  41. 41.
    Winter JM, Cameron JL, Campbell KA, et al.: 1423 Pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006;10:1199–1210.CrossRefPubMedGoogle Scholar
  42. 42.
    Richter A, Niedergethmann M, Sturm JW, et al.: Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003;27:324–329.CrossRefPubMedGoogle Scholar
  43. 43.
    Varadhachary GR, Tamm EP, Abbruzzese JL, et al.: Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006;13:1035–1046.CrossRefPubMedGoogle Scholar
  44. 44.
    Katz MHG, Pisters PWT, Evans DB, et al.: Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008;206:833–846.CrossRefPubMedGoogle Scholar
  45. 45.
    NCCN Clinical Practice Guidelines in Oncology, Pancreatic Adenocarcinoma National Comprehensive Cancer Network v1.2008.Google Scholar
  46. 46.
    Jonker D, Boutell E, Kamra J, et al.: Gastrointestinal Cancer Disease Site Group. Cheomtherapy or radiotherapy for resectable pancreatic adenocarcinoma: Clincal Practice Guideline. Evidence-based Series #2–23 Program in Evidence-based care (PEBC), Cancer Care Ontario (CCO), November, 2007.Google Scholar
  47. 47.
    Pancreatic Section of the British Society of Gastroenterology, Pancreatic Society of Great Britain and Ireland, Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, Royal College of Pathologists, Special Interest Group for Gastrointestinal Radiology. Guidelines for the management of patients with pancreatic cancer: periampuallary and ampullary carcinomas. Gut 2005;54(Suppl V):v1–v16.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Naimish Pandya
    • 1
  • Michael C. Garofalo
    • 2
  • William F. Regine
    • 3
  1. 1.Department of MedicineUniversity of Maryland School of MedicineBaltimoreUSA
  2. 2.Department of Radiation OncologyUniversity of Maryland School of MedicineBaltimoreUSA
  3. 3.Department of Radiation OncologyUniversity of Maryland School of MedicineBaltimoreUSA

Personalised recommendations